Cargando…

Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis

Glucagon-like peptide-1 (GLP-1) receptor agonists are used to treat diabetes, but their effects on nonalcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) remain unclear. In this study, mice with streptozotocin- and high-fat diet-induced diabetes and NASH were subcu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kojima, Motoyasu, Takahashi, Hirokazu, Kuwashiro, Takuya, Tanaka, Kenichi, Mori, Hitoe, Ozaki, Iwata, Kitajima, Yoichiro, Matsuda, Yayoi, Ashida, Kenji, Eguchi, Yuichiro, Anzai, Keizo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460814/ https://www.ncbi.nlm.nih.gov/pubmed/32785012 http://dx.doi.org/10.3390/ijms21165722

Ejemplares similares

PDCD4 Knockdown Induces Senescence in Hepatoma Cells by Up-Regulating the p21 Expression
por: Guo, Jing, et al.
Publicado: (2019)

Re-evaluation of glycated hemoglobin and glycated albumin with continuous glucose monitoring system as markers of glycemia in patients with liver cirrhosis
por: Isoda, Hiroshi, et al.
Publicado: (2017)

Re-evaluation of glycated hemoglobin and glycated albumin with continuous glucose monitoring system as markers of glycemia in patients with liver cirrhosis
por: Isoda, Hiroshi, et al.
Publicado: (2017)

Influence of muscle fiber type composition on early fat accumulation under high-fat diet challenge
por: Hua, Ning, et al.
Publicado: (2017)

HSPA8 Single-Nucleotide Polymorphism Is Associated with Serum HSC70 Concentration and Carotid Artery Atherosclerosis in Nonalcoholic Fatty Liver Disease
por: Zhao, Wenli, et al.
Publicado: (2022)

Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms
por: Takahashi, Hirokazu, et al.
Publicado: (2018)

Mechanisms of PKC-Mediated Enhancement of HIF-1α Activity and its Inhibition by Vitamin K2 in Hepatocellular Carcinoma Cells
por: Xia, Jinghe, et al.
Publicado: (2019)

Efficacy of pegylated interferon plus ribavirin in combination with corticosteroid for two cases of combined hepatitis C and autoimmune hepatitis
por: Oeda, Satoshi, et al.
Publicado: (2012)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

TYK2 Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients
por: Mori, Hitoe, et al.
Publicado: (2021)

Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees
por: Murayama, Kenichiro, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
por: Mantovani, Alessandro, et al.
Publicado: (2021)

Regulation of interferon signaling and HCV-RNA replication by extracellular matrix
por: Kuwashiro, Takuya, et al.
Publicado: (2018)

Correction: Medaka as a model for human nonalcoholic steatohepatitis
por: Matsumoto, Toshihiko, et al.
Publicado: (2023)

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
por: Tokushige, Katsutoshi, et al.
Publicado: (2021)

SARS-CoV-2 Infection and Pancreatic β Cell Failure
por: Mine, Keiichiro, et al.
Publicado: (2021)

Administration of Jerusalem artichoke reduces the postprandial plasma glucose and glucose-dependent insulinotropic polypeptide (GIP) concentrations in humans
por: Takahashi, Hirokazu, et al.
Publicado: (2022)

Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation
por: Kuwashiro, Shinya, et al.
Publicado: (2011)

Decrease in fasting insulin secretory function correlates with significant liver fibrosis in Japanese non‐alcoholic fatty liver disease patients
por: Araki, Norimasa, et al.
Publicado: (2020)

Genetic Susceptibility of the Host in Virus-Induced Diabetes
por: Mine, Keiichiro, et al.
Publicado: (2020)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Hydroxynonenal Causes Hepatocyte Death by Disrupting Lysosomal Integrity in Nonalcoholic Steatohepatitis
por: Seike, Takuya, et al.
Publicado: (2022)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

Effect of skin–capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease
por: Kimura, Syunichiro, et al.
Publicado: (2021)

Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis
por: Huang, Peng, et al.
Publicado: (2018)

Wilson's disease masquerading as nonalcoholic steatohepatitis
por: Mahmood, Sabina, et al.
Publicado: (2009)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
por: Lam, Mindy C.W., et al.
Publicado: (2012)

The effect of β-caryophyllene on nonalcoholic steatohepatitis
por: Arizuka, Naoya, et al.
Publicado: (2017)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Repurposing drugs to target nonalcoholic steatohepatitis
por: Sookoian, Silvia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0lpch4cu2rgrgkhpeu1p17sua7